A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2016
Price : $35 *
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 08 Jul 2016 Status changed from recruiting to completed.
- 22 May 2014 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
- 22 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.